title: Serum Testosterone, 17β-Estradiol and PSA Levels in Subjects with Prostate Disorders.
abstract: Prostate carcinoma is the most frequently diagnosed malignancy and the second leading cause of death as a result of cancer in men in the US and other parts of the world. There are conflicting reports on the serum levels of testosterone and 17β-estradiol (E2) in benign prostatic hyperplasia (BPH) and prostate cancer. This study was designed to evaluate the serum concentrations of these hormones in patients with these disorders. Serum levels of prostate specific antigen (PSA), total testosterone and estradiol were determined in 228 subjects comprising of 116 subjects with BPH, 62 subjects with prostate cancer (CaP) and 50 age-matched apparently healthy controls, using ELISA methods. PSA levels were significantly elevated (p < 0.05) in BPH subjects than controls, while there was no significant difference (p > 0.05) in testosterone and estradiol levels of these subjects. PSA and estradiol levels were significantly higher (p < 0.05) in CaP subjects than in controls, while there was no observed significant difference (p > 0.05) in testosterone levels. CaP subjects had significantly raised PSA, testosterone, and estradiol levels than BPH subjects. The mean molar ratio of testosterone: E2 was lowest among CaP patients (134:1) and highest among controls (166:1). Significant positive correlation between PSA and 17β-estradiol was observed in prostate disorders (BPH and CaP patients: r = 0.347; p = 0.000). Significant negative correlations between testosterone and PSA were also observed among BPH patients (r = -0.221, p = 0.049) and control subjects (r = -0.490, p = 0.000). No significant correlation existed between testosterone and PSA in CaP patients (r = 0.051, p = 0.693). Correlations between age and estradiol in both BPH and CaP were not significant (p > 0.05). This study has shown that, there was a significant increase in serum estradiol in CaP subjects, while the testosterone levels in both BPH and CaP subjects were not different from those of controls.
authors: Department of Chemical Pathology, College of Health Sciences, University of Uyo, Uyo, Nigeria.
authors: Anthony J
authors: AJ
authors: Usoro
authors: Endocrinology/Research Unit, Chemical Pathology Laboratory, University of Uyo Teaching Hospital, Uyo, Nigeria.
authors: Aniebietabasi S
authors: AS
authors: Obot
authors: Department of Chemical Pathology, College of Health Sciences, University of Uyo, Uyo, Nigeria.
authors: Itemobong S
authors: IS
authors: Ekaidem
authors: Department of Surgery, College of Health Sciences, University of Uyo, Uyo, Nigeria.
authors: Okon E
authors: OE
authors: Akaiso
authors: Department of Chemical Pathology, College of Medical Sciences, University of Calabar, Calabar, Nigeria.
authors: Alphonsus E
authors: AE
authors: Udoh
authors: Oxidative Stress Research Centre, Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville, 7535 South Africa.
authors: O
authors: O
authors: Akinloye
keywords: BPH; Estradiol; Molar ratio; PSA; Prostate cancer; Testosterone
references: Urol Clin North Am. 2003 May;30(2):209-17
references: 12735498
references: J Clin Endocrinol Metab. 2001 Feb;86(2):724-31
references: 11158037
references: N Engl J Med. 2004 May 27;350(22):2239-46
references: 15163773
references: Endocrinology. 2001 Jun;142(6):2443-50
references: 11356693
references: J Natl Med Assoc. 1998 Nov;90(11 Suppl):S720-3
references: 9828589
references: Prostate. 2000 Oct 1;45(2):87-100
references: 11027407
references: Prostate. 2002 Aug 1;52(3):213-35
references: 12111697
references: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references: 15661684
references: N Engl J Med. 2003 Dec 18;349(25):2387-98
references: 14681504
references: FASEB J. 2008 May;22(5):1512-20
references: 18055862
references: J Clin Invest. 2002 Jul;110(2):219-27
references: 12122114
references: Cancer Res. 1991 Jul 1;51(13):3445-50
references: 1711411
references: J Natl Cancer Inst Monogr. 2000;(27):39-66
references: 10963619
references: Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30
references: 8650195
references: Int J Cancer. 2004 Jan 20;108(3):418-24
references: 14648709
references: West Afr Med J Niger Med Dent Pract. 1973 Dec;22(6):108-11
references: 4808109
references: J Natl Cancer Inst. 2000 Dec 20;92(24):2009-17
references: 11121463
references: J Natl Med Assoc. 2002 Jul;94(7):619-27
references: 12126288
references: Front Biosci. 2006 May 01;11:1388-413
references: 16368524
references: Curr Opin Urol. 2000 Sep;10(5):415-20
references: 11005445
references: J Natl Cancer Inst. 1986 Jan;76(1):45-8
references: 3455741
references: J Clin Invest. 1983 Nov;72(5):1772-7
references: 6195192
references: Eur Urol. 1999;35(5-6):362-9
references: 10325490
references: Int Rev Cytol. 2000;199:65-116
references: 10874577
references: J Natl Med Assoc. 1999 Mar;91(3):159-64
references: 10203918
references: J Urol. 1981 Sep;126(3):372-5
references: 7277602
references: Urol Int. 2008;80(2):134-40
references: 18362481
references: J Clin Endocrinol Metab. 2001 Aug;86(8):3467-77
references: 11502765
references: J Natl Cancer Inst. 1996 Aug 21;88(16):1118-26
references: 8757191